Page 9 - Vered Caplan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Orgenesis teams with Dong-a University Hospital in South Korea and Cure Therapeutics to utilize its Mobile Processing Units and Labs, or OMPULs OMPULs are multi-purpose mobile autonomous good manufacturing practice facilities intended to develop, optimize, and manufacture cell and gene therapies at the point of use The latest collaboration follows a recent joint venture agreement between Orgenesis and Cure Therapeutics to target cancer and infectious diseases Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) announced Monday it has signed a collaboration agreement with Dong-a University Hospi...

Orgenesis signs JV with Korean CGT developer US headquartered company, Orgenesis, and South Korea-based, Cure Therapeutics, have signed a JV deal to advance the development, regulatory approval, and commercialization of point of care production for both companies’ cell and gene therapies and immunotherapies. “The joint venture and partnership with Orgenesis will provide a significant international route to market for our immunotherapies targeting cancers and infectious diseases,”​ said David Kim, CEO of Cure Therapeutics. Under the deal, the parties will...